ubiquitin conjugating enzyme E2 S pseudogene 2Genealiases: []
Q-omics provides the consensus-scored UBE2SP2 profile across patient tissues and cancer cell-line models. UBE2SP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBE2SP2 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, UBE2SP2 RNA expression shows 15,403 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, HNSC, and THYM as cancer lineages where UBE2SP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2SP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2SP2 survival associations across molecular data types. UBE2SP2 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2SP2 RNA expression–survival associations across cancer types. High UBE2SP2 expression shows unfavorable associations in ACC, UVM, MESO, KIRP, KIRC and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBE2SP2 RNA expression.
This table summarizes UBE2SP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2SP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2SP2 shows higher tumor expression in HNSC, COAD, LUAD, LIHC, UCEC and LUSC. The HNSC box plot shows higher UBE2SP2 RNA expression in tumor versus normal tissue (log2 FC = +0.670, t-test p < 0.001).
This table shows molecular features associated with UBE2SP2 in patient tissues and cancer cell lines. In patient samples, UBE2SP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
